Management of an isolated thymic mass after primary therapy for lymphoma by Anchisi, S. et al.
Annals of Oncology 9: 95-100. 1998.
© 1998 Kluwer Academic Publishers. Printed in the Netherlands.
Clinical case
Management of an isolated thymic mass after primary therapy for lymphoma
S. Anchisi, R. Abele, M. Guetty-Alberto & P. Alberto
Division of Oncology, Department of Medicine, University Hospital, Geneva, Switzerland
Key words: CT scan, galliumscintigraphy, Hodgkin's disease, lymphoma, residual mass, thymus hyperplasia
Introduction
The appearance of an anterior mediastinal mass during
the follow-up of patients successfully treated for lym-
phoma is worrisome, and may suggest treatment failure.
However, benign 'rebound' thymic hyperplasia (TH), a
well documented phenomenon in children [1-3] and in
young adults treated for malignant testicular teratoma
[4], is an important differential diagnosis even in the
adult population [5].
Case reports
Between July 1990 and December 1994, we observed
two cases of TH among 58 adults treated consecutively
at our institution. Thirty of the 58 had de novo Hodgkin's
disease (HD) and 28 had aggressive non-Hodgkin's
lymphoma (NHL). During the same period, another
case was diagnosed by one of us in private practice.
Casel
A 32-year-old man presented with a diffuse centroblastic
B-cell NHL of the nasopharynx, stage IIA. Thymic and
mediastinal lymph node enlargements were documented
by thoracic computerized tomography (CT, Figure la).
He obtained a complete response (CR) after three
courses of BCDVP chemotherapy (bleomycin, cyclo-
phosphamide, doxorubicin, vincristine and prednisone)
with intrathecal methotrexate CNS prophylaxis. A total
of six courses was given, followed by radiation therapy
(36 Gy) to his Waldeyer's ring and cervical lymph nodes.
Eight months later, left-sided lower cervical and axillary
adenopathies were noted. A thoracic CT revealed an
enlarged thymic mass in comparison with the initial
study, but without abnormal mediastinal lymph nodes
(Figure lb). A surgical biopsy of the axillary adenopathy
disclosed a benign lymphoid hyperplasia. Four months
later the persisting thymic mass, measuring 6 x 4.5 x
1 cm, was surgically excised. Histology with immuno-
staining showed a benign thymic hyperplasia, with adi-
pose tissue constituting less than 40% of the total mass.
The patient is still in CR 51 months after the end of
treatment.
Case 2
A 26-year-old woman presented with a stage IVB
nodular sclerosing HD, with liver and spleen infiltration
and a bulky mediastinum.
Magnetic resonance imaging (MRI) disclosed a dif-
fuse infiltration of the thoracic and lumbar vertebral
bodies. The result of a bone-marrow biopsy was normal.
Five courses of VEMP chemotherapy (vincristine, eto-
poside, mitoxantrone, prednisone) produced a partial
response greater than 75%. The treatment was intensi-
fied with a BEAM chemotherapy (carmustine, etoposide,
cytosine arabinoside, melphalan), followed by an autol-
ogous bone marrow transplant (BMT). Four months
later, the planned CT revealed that the residual mass in
the antero-superior mediastinum was enlarging, meas-
uring 4 x 1.5 x 3 cm. There was no other sign of
lymphoma progression, and the mass was surgically
excised. Histology showed TH and fibrotic lymph nodes.
The patient is still in CR 30 months after completion of
treatment.
Case 3
A 30-year-old female presented with a stage IIA diffuse
centroblastic B-cell NHL of the nasopharynx. She en-
tered CR after three courses of BCDVP chemotherapy
with intrathecal methotrexate CNS prophylaxis. A total
of six courses of chemotherapy were given and radio-
therapy (34 Gy) was delivered to her Waldeyer's ring and
cervical lymph nodes. Two months after the end of treat-
ment, a thoracic CT showed an isolated thymic mass
measuring 4 x 2 x 3 cm (Figure 2a), somewhat larger
than prior to treatment. A new work-up was performed
and CR was confirmed. A presumptive diagnosis of TH
was made, and remained unchanged for three months.
Thirteen months later CT showed an important regres-
sion, with the thymus measuring 2 x 1.2 x 1.5 cm
Figure 1. Thoracic CT scan of case no. 1. (a) At diagnosis, prior to treatment. Heterogeneous triangular mass in the anterior mediastinum,
measuring 3 x 2 x 3.5 cm., with enlarged mediastinal lymph nodes (see 'A-B'). (b) Eight months after completion of treatment. Heterogeneous,
triangular, partly bi-lobed mass in the anterior mediastinum (see 'o'), measuring 4 x 2 x 4.5 cm., without enlarged mediastinal lymph nodes.
(Figure 2b). The patient is currently in persistent CR 28
months after cessation of treatment.
Discussion
Due to the potential for lymphomatous involvement of
the thymus, disclosure of a new or growing anterior
mediastinal mass after successful treatment of lym-
phoma is ominous. During the first six months post-
therapy (occasionally up to one year) the relevant diag-
noses are essentially relapse, TH, and residual 'fibrotic'
mass if the anterior mediastinum was already involved
at presentation. We will confine our discussion to relapse
versus TH.
Does any specific radiological sign differentiate
between lymphoma recurrence and TH?
CTandMRI
On CT the appearance of normal thymus in the anterior
mediastinal space is described as a triangular or bi-
lobed structure, with soft-tissue density, whose size
varies according to age [6-8].
Thymic enlargement is usually suspected if the thick-
ness of at least one lobe is greater than two standard
deviations above those of age-related controls [2, 6].
Mackall et al. [9] defined TH as a two-fold or greater
increase in thymic volume during the first year after
chemotherapy over the thymic volume at presentation.
Lucker and Siegel [2] studied 23 children who were
followed with thoracic CT after treatment of HD with
mediastinal involvement. They reported TH in four
(17%) children who were in CR. TH was defined as an
isolated enlargement of the thymus, observed on the first
follow-up scan.
Heron et al. [6] studied 100 pathological thoracic CT
in 84 patients (aged 15-33 years) with HD. One case of
thymic cyst without nodal enlargement was observed
out of 50 CT performed at the time of suspected relapse.
In contrast, seven cases of thymic enlargement with
proven HD relapse were associated with enlarged
mediastinal lymph nodes. The authors report five cases
of TH, not included in the above series, which occurred
4 to 10 months after cessation of treatment.
On MRI the signal intensity of the normal thymus is
less than that of surrounding fat on Tl-weighted image,
and approaches that of fat on T2-weighted scans. TH is
described as homogeneous and uniform, as opposed to
that of lymphoma [8].
In most if not all cases of TH, the enlarging mass
retained the characteristic shape of normal thymus [2,4,
6-8].
Is Gallium-67 scan helpful?
Reported cases of TH on thoracic CT are mostly asso-
ciated with positive [1, 9-15] Ga-67 scans. Negative scans
are described [1], particularly in instances of thymic cyst
or hemorrhage [5, 12].
Peylan-Ramu et al. [1] studied 62 young long-term
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Figure 2 Thoracic CTscan of case no. 2. (a) Thymic enlargment ( 4 x 2 x 3 cm) diagnosed two months after completion of treatment, (b) Control
CTscan 13 months later, showing significant regression of the thymic mass (2 x 1.2 x 1.5 cm).
survivors followed with Ga-67 scans after treatment of
NHL. Ten (16%) TH, defined as an isolated antero-
superior mediastinal uptake, were observed one to eight
months after completion of chemotherapy. In this study,
only four children had both Ga-67 scans and thoracic
CT. The CT revealed a thymic mass in one child with
negative scintigraphy and in one of three with positive
scintigraphy.
Since Ga-67 scan cannot distinguish between lym-
phoma relapse and TH, its main utility would be to
disclose other positive sites suggestive of relapse. Yet, in
a study of 101 HD patients, post-treatment Ga-67 scan
identified only 4 of 20 patients who eventually failed,
and Ga-67 scan was the sole predictor of failure for only
two patients [16].
Could other radiological techniques contribute to the
diagnosis of TH?
To our knowledge no prospective studies have been per-
formed to assess the accuracy and practical usefulness of
other radiological techniques for the diagnosis of TH
[17] such as PET-scan, thallium-201 scintigraphy [10] or
octreo-scan [15]. There is no proof that they can really
differentiate between proliferating 'normal reactive' and
'lymphomatous' lymphocytes.
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Table I. Characteristics of some recently reported cases of TH disclosed on CT after primary therapy for lymphoma in adults.
Reference
[11]
[12]
[12]
[13]
[14]
[20]
PS
PS
PS
Age (years)
22
40
17
18
19
31
32
26
30
Primary
diagnosis
HD
NHL
HD
HD
HD
HD
NHL
HD
NHL
Primary
treatment
CX
CX
CX + RX
CX
CX
CX
CX + RX
CX + ABMT
CX + RX
Time to
diagnosis of
TH after
therapy
(months)
4
12
4
4
6
7
8
4
2
Ga-67 scan
Pos.
Pos.
Neg.
Pos.
Yes
ND
ND
ND
ND
Histology
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
ND
Duration of
TH (months)
2
4 (Ga-67),
8 (CT)
3
>11
4
13
Comments
Residual mass
Multiple cysts
Hyper-thyroidy
Abbreviations: CX - chemotherapy; RX - radiotherapy; Pos. - positive; Neg. - negative; ND - not done; PS - present series.
Radiology, summary
As pointed out by these studies [1, 2, 6,7], the absence of
concurrent lymph node enlargement or other signs of
relapsing lymphoma, and the timing of thymic enlarge-
ment or uptake, are the major clues favoring the diag-
nosis of TH, which retains the characteristic shape of
normal thymus.
Rebound thymic hyperplasia
Histology
Rebound TH correspond to a true hyperplasia involving
both the cortex and the medulla [18]. It is to be distin-
guished from 'thymic lymphoid follicular hyperplasia' of
the medulla or 'germinal center hyperplasia', which can
be associated with myastenia gravis [18]. In 30%-50% of
the latter CTscan shows a normal-sized thymus [7].
Pathophysiology of TH
As illustrated by Mackall et al. [9], the regenerative
capacity of thymopoiesis decreased with age, which
could represent a decline in the intrinsic capacity of
lymphopoietic stem cells and/or changes in the thymic
microenvironment. This group showed an inverse rela-
tion between the patients' ages and the recovery of CD4+
T-lymphocytes six months after chemotherapy. This re-
covery was correlated quantitatively with the appear-
ance of CD45RA+-naive T-lymphocytes in the periph-
eral blood and with thymic enlargement (P - 0.015). At
three months post-therapy, there was no relationship
among age, TH, and CD8-positive lymphocytes which
had returned to baseline [19].
Clinical manifestation ofTH, and associated situation
TH is asymptomatic and usually regresses within a few
months, but long-standing cases are reported [1, 20].
'Rebound' TH has been associated with prolonged sur-
vival and may be a good prognostic sign [4, 5].
Rebound TH has been described following hyper-
thyroidy or resolution of important stress in children
(burns, surgery, corticotherapy) [18], and treatment of
Cushing's syndromes [21].
TH following chemotherapy and/or radiotherapy is
not restricted to patients treated for lymphoma. Kissin
et al. [4] reported that 11.6% of (14 of 120) patients
developed TH 3 to 14 months after cessation of chemo-
therapy for malignant testicular teratoma, and that one
TH occurred among 80 patients treated by surgery only.
Three cases of TH described by Mackall et al. [9] oc-
curred among children treated for sarcoma.
Is TH after primary treatment for lymphoma a plausible
diagnosis at any age?
'Rebound' TH has essentially been described in children
and adolescents, in whom frequencies of 16%: 10 of 62 (1);
17%: 4 of 23 (2) and 12%: 6 of 51 (3) have been found.
The 10 patients reported by Peylan-Ramu et al. [1] were
younger than 15 years.
Though infrequent, TH has been observed in adults
with lymphoma. In a review of the literature, Langer et
al. [5] found 21 cases following treatment for HD, with a
median age of 23 years (range 8-40). More recently,
further cases of TH following treatment of HD or NHL
have been described in adults [11-14, 20] and are listed
in Table 1.
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Particular aspects of TH illustrated by our cases
Cases no. 1 and no. 3 showed an enlarged thymus before
any treatment, which was not considered to be infiltrated.
This anomaly persisted as a residual growing mass after
completion of treatment and achievement of a CR. TH
could already have been present at the time of presenta-
tion [6], as shown by two cases reported by Langer et al.
[5], and by the study of Moul et al. [22], which disclosed
at presentation four TH in 221 patients with germ cell
testicular tumors.
Case no. 2 presented a growing residual mediastinal
mass after autologous BMT for HD. Diagnosis of TH
was made by surgical biopsy. Thymic hyperplasia occur-
ring after allogeneic BMT has been described in a nine-
year-old child suffering from an acute lymphoblastic
leukemia [23]. In our case, with bulky mediastinum at
presentation, thymus was considered to be infiltrated by
HD. It demonstrates that TH must be considered in the
differential diagnosis of a residual mass.
Management ofTH
We acknowledge, with Peylan-Ramu et al. [1], that a
careful clinical and radiological follow-up is frequently
sufficient. There is no need for specific treatment.
Although regression of the mass with steroid challenge
60 mg/m2 daily for 7-10 days [24] could favor TH if the
initial diagnosis was not steroid-sensitive leukemia or
lymphoma.
An invasive diagnostic procedure can usually be
avoided, but should be considered if a new oncological
treatment is planned, in order to obtain histological
confirmation of lymphoma relapse.
Conclusion
Thymic hyperplasia following chemotherapy and/or
radiotherapy for lymphoma is probably not rare in the
adult population up to the age of 40. As illustrated by
our three cases, TH can be present before any treatment
and/or recognized as a growing anterior mediastinal
mass during the first months after therapy (up to one
year). It should be included in the differential diagnosis
of a residual mass. Using strict diagnostic criteria (iso-
lated radiological mass retaining the characteristic shape
and density of normal thymus, without mediastinal aden-
opathy and without symptoms or signs of lymphoma
relapse), a careful clinical and radiological follow-up is
generally sufficient. An invasive diagnostic procedure
can usually be avoided, but should be considered before
administering a new oncological treatment, in order to
ascertain lymphoma relapse and rule out TH.
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